Vaccination of the global population against COVID-19 is a great scientific, logistical, and
moral challenge. Despite the rapid development and authorization of several full-length …

The rapid development and deployment of mRNA and adenovirus-vectored vaccines
against coronavirus disease 2019 (COVID-19) continue to astound the global scientific …

Global deployment of vaccines that can provide protection across several age groups is still
urgently needed to end the COVID-19 pandemic, especially in low-and middle-income …

Background We assessed the efficacy of a receptor-binding domain (RBD)-based protein
subunit COVID-19 vaccine. Methods A randomised Phase-1/2 trial followed by a Phase-2 …

Ongoing severe acute respiratory syndrome coronavirus–2 (SARS-CoV-2) vaccine
development is focused on identifying stable, cost-effective, and accessible candidates for …

There is an urgent need for an accessible and low-cost COVID-19 vaccine suitable for low-
and middle-income countries. Here, we report on the development of a SARS-CoV-2 …

There is a great need for the development of vaccines that induce potent and long-lasting
protective immunity against SARS-CoV-2. Multimeric display of the antigen combined with …

Develo** affordable and easily manufactured SARS-CoV-2 vaccines will be essential to
achieve worldwide vaccine coverage and long-term control of the COVID-19 pandemic …

Introduction The development of a yeast-expressed recombinant protein-based vaccine
technology co-developed with LMIC vaccine producers and suitable as a COVID-19 vaccine …